Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease - PubMed
a day ago
- #Type 1 Diabetes
- #CKM Therapies
- #Chronic Kidney Disease
- Study investigates the use of cardio-kidney-metabolic (CKM) therapies (GLP-1RA and SGLT2i) in adults with Type 1 diabetes and chronic kidney disease (CKD).
- More than 10% of patients with Type 1 diabetes and CKD used CKM therapies, showing a significant reduction in urinary albumin-to-creatinine ratio (UACR).
- CKM therapies were found to be safe, with no increased rates of hypoglycemia or diabetic ketoacidosis.
- The study utilized data from Optum's Market Clarity database, analyzing 253 patients with sufficient UACR data.
- Findings suggest CKM therapies could be beneficial for kidney function in Type 1 diabetes patients with CKD, warranting further randomized clinical trials.